{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T23:36:14Z","timestamp":1721864174617},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2011,4,9]],"date-time":"2011-04-09T00:00:00Z","timestamp":1302307200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Theory Biosci."],"published-print":{"date-parts":[[2011,9]]},"DOI":"10.1007\/s12064-011-0127-y","type":"journal-article","created":{"date-parts":[[2011,4,8]],"date-time":"2011-04-08T13:36:15Z","timestamp":1302269775000},"page":"203-210","source":"Crossref","is-referenced-by-count":16,"title":["Stochastic dynamics of leukemic cells under an intermittent targeted therapy"],"prefix":"10.1007","volume":"130","author":[{"given":"Nicola","family":"Pizzolato","sequence":"first","affiliation":[]},{"given":"Dominique","family":"Persano Adorno","sequence":"additional","affiliation":[]},{"given":"Davide","family":"Valenti","sequence":"additional","affiliation":[]},{"given":"Bernardo","family":"Spagnolo","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2011,4,9]]},"reference":[{"key":"127_CR1","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1038\/sj.bjc.6603310","volume":"95","author":"LH Abbott","year":"2006","unstructured":"Abbott LH, Michor F (2006) Mathematical models of targeted cancer therapy. Br J Cancer 95:1136\u20131141","journal-title":"Br J Cancer"},{"key":"127_CR2","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1038\/ncponc1317","volume":"6","author":"N Andr\u00e9","year":"2009","unstructured":"Andr\u00e9 N, Pasquier E (2009) Response to \u201cintermittent androgen blockade should be regarded as standard therapy in prostate cancer\". Nat Clin Pract Oncol 6:E1","journal-title":"Nat Clin Pract Oncol"},{"key":"127_CR3","doi-asserted-by":"crossref","first-page":"2163a","DOI":"10.1126\/science.293.5538.2163a","volume":"293","author":"C Barthe","year":"2001","unstructured":"Barthe C, Cony-Makhoul P, Melo JV, Reiffers J, Mahon FX (2001) Roots of clinical resistance to STI-571 cancer therapy. Science 293:2163a","journal-title":"Science"},{"key":"127_CR4","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.jtbi.2005.11.018","volume":"241","author":"Y Brumer","year":"2006","unstructured":"Brumer Y, Michor F, Shakhnovich EI (2006) Genetic instability and the quasispecies model. J Theor Biol 241:216\u2013222","journal-title":"J Theor Biol"},{"key":"127_CR5","doi-asserted-by":"crossref","first-page":"912","DOI":"10.4161\/cbt.6.6.4101","volume":"6","author":"F Belloc","year":"2007","unstructured":"Belloc F, Moreau-Gaudry F, Uhalde M, Cazalis L, Jeanneteau M, Lacombe F, Praloran V, Mahon FX (2007) Imatinib and nilotinib induce apoptosis of chronic myeloid leukemia cells through a bim-dependant pathway modulated by cytokines. Cancer Biol Ther 6:912\u2013919","journal-title":"Cancer Biol Ther"},{"key":"127_CR6","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1634\/stemcells.2006-0136","volume":"24","author":"D Dingli","year":"2006","unstructured":"Dingli D, Michor F (2006) Successful therapy must eradicate cancer stem cells. Stem Cells 24:2603\u20132610","journal-title":"Stem Cells"},{"key":"127_CR7","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1080\/10428190600565057","volume":"47","author":"E Faber","year":"2006","unstructured":"Faber E, Nau\u0161ov\u00e1 J, Jaro\u0161ov\u00e1 M, Egorin MJ, Holzerov\u00e1 M, Ro\u017emanov\u00e1 S, Mare\u0161ov\u00e1 I, Divok\u00fd V, Indr\u00e1k K (2006) Intermittent dosage of imatinib mesylate in CML patients with a history of significant hematologic toxicity after standard dosing. Leuk Lymphoma 47:1082\u20131090","journal-title":"Leuk Lymphoma"},{"key":"127_CR8","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1093\/genetics\/163.4.1527","volume":"163","author":"SA Frank","year":"2003","unstructured":"Frank SA, Iwasa Y, Nowak M (2003) Patterns of cell division and the risk of cancer. Genetics 163:1527\u20131532","journal-title":"Genetics"},{"key":"127_CR9","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/j.1365-2184.2006.00368.x","volume":"39","author":"AL Garner","year":"2006","unstructured":"Garner AL, Lau YY, Jordan DW et\u00a0al. (2006) Implications of a simple mathematical model to cancer cell population dynamics. Cell Prolif 39:15\u201328","journal-title":"Cell Prolif"},{"key":"127_CR10","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1038\/sj.leu.2403426","volume":"18","author":"A Hochhaus","year":"2004","unstructured":"Hochhaus A, La Ros\u00e9e P (2004) Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance. Leukemia 18:1321\u20131331","journal-title":"Leukemia"},{"key":"127_CR11","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1159\/000118786","volume":"188","author":"M Horn","year":"2008","unstructured":"Horn M, Loeffler M, Roeder I (2008) Mathematical modeling of genesis and treatment of chronic myeloid leukemia. Cells Tissues Organs 188:236\u2013247","journal-title":"Cells Tissues Organs"},{"key":"127_CR12","unstructured":"Ichimaru M, Ishimaru T, Mikami M, Yamada Y, Ohkita T (1981) Incidence of leukemia in a fixed cohort of atomic bomb survivors and controls, Hiroshima and Nagasaki, October 1950\u2013December 1978. Technical Report no. 13-81. Hiroshima, Radiation Effects Research Foundation"},{"key":"127_CR13","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1534\/genetics.166.3.1571","volume":"166","author":"Y Iwasa","year":"2004","unstructured":"Iwasa Y, Michor F, Nowak M (2004) Stochastic tunnels in evolutionary dynamics. Genetics 166:1571\u20131579","journal-title":"Genetics"},{"key":"127_CR14","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1093\/genetics\/148.4.1483","volume":"148","author":"AL Jackson","year":"1998","unstructured":"Jackson AL, Loeb LA (1998) The mutation rate and cancer. Genetics 148:1483\u20131490","journal-title":"Genetics"},{"key":"127_CR15","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/35101031","volume":"1","author":"AG Knudson","year":"2001","unstructured":"Knudson AG (2001) Two genetic hits (more or less) to cancer. Nat Rev Cancer 1:157\u2013170","journal-title":"Nat Rev Cancer"},{"key":"127_CR16","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.tpb.2007.08.003","volume":"72","author":"NL Komarova","year":"2007","unstructured":"Komarova NL, Wodarz D (2007) Stochastic modeling of cellular colonies with quiescence: an application to drug resistance in cancer. Theor Popul Biol 72:523\u2013538","journal-title":"Theor Popul Biol"},{"key":"127_CR17","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1073\/pnas.96.4.1492","volume":"96","author":"LA Loeb","year":"2002","unstructured":"Loeb LA, Essigmann JM et\u00a0al.(2002) Lethal mutagenesis of HIV with mutagenic nucleoside analogs. Proc Natl Acad Sci 96:1492\u20131497","journal-title":"Proc Natl Acad Sci"},{"key":"127_CR18","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/ncponc1276","volume":"6","author":"G Martinelli","year":"2009","unstructured":"Martinelli G, Soverini S, Iacobucci I, Baccarani M (2009) Intermittent targeting as a tool to minimize toxicity of tyrosine kinase inhibitor therapy. Nat Clin Pract Oncol 6:68\u201369","journal-title":"Nat Clin Pract Oncol"},{"key":"127_CR19","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1098\/rspb.2003.2483","volume":"270","author":"F Michor","year":"2003","unstructured":"Michor F, Nowak M, Frank SA, Iwasa Y (2003) Stochastic elimination of cancer cells. Proc R Soc Lond B 270:2017\u20132024","journal-title":"Proc R Soc Lond B"},{"key":"127_CR20","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1038\/nature03669","volume":"435","author":"F Michor","year":"2005","unstructured":"Michor F, Hughes TP, Iwasa Y, Branford S, Shah NP, Sawyers CL, Nowak MA (2005) Dynamics of chronic myeloid leukemia. Nature 435:1267\u20131270","journal-title":"Nature"},{"key":"127_CR21","doi-asserted-by":"crossref","first-page":"261","DOI":"10.2174\/138161206775201956","volume":"12","author":"F Michor","year":"2006","unstructured":"Michor F, Nowak M, Iwasa Y (2006) Evolution of resistance to cancer therapy. Curr Pharm Des 12:261\u2013271","journal-title":"Curr Pharm Des"},{"key":"127_CR22","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1634\/stemcells.2006-0638","volume":"25","author":"F Michor","year":"2007","unstructured":"Michor F (2007) Chronic myeloid leukemia blast crisis arises from progenitors. Stem Cells 25:1114\u20131118","journal-title":"Stem Cells"},{"key":"127_CR23","volume-title":"The statistical processes of evolutionary theory","author":"PAP Moran","year":"1962","unstructured":"Moran PAP (1962) The statistical processes of evolutionary theory. Oxford: Clarendon Press"},{"key":"127_CR24","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1055\/s-2002-34939","volume":"127","author":"MC M\u00fcller","year":"2002","unstructured":"M\u00fcller MC, Lahaye T, Hochhaus A (2002) Resistance to tumor specific therapy with imatinib by clonal selection of mutated cells. Dtsch Med Wochenschr 127:2205\u20132207","journal-title":"Dtsch Med Wochenschr"},{"key":"127_CR25","doi-asserted-by":"crossref","first-page":"16226","DOI":"10.1073\/pnas.202617399","volume":"99","author":"MA Nowak","year":"2002","unstructured":"Nowak MA, Komarova NL, Sengupta A, Jallepalli PV, Shih I, Vogelstein B, Lengauer C (2002) The role of chromosomal instability in tumor initiation. Proc Natl Acad Sci 99:16226\u201316231","journal-title":"Proc Natl Acad Sci"},{"key":"127_CR26","doi-asserted-by":"crossref","first-page":"541","DOI":"10.2478\/s11534-009-0020-1","volume":"7","author":"N Pizzolato","year":"2009","unstructured":"Pizzolato N, Valenti D, Persano Adorno D et\u00a0al. (2009) Evolutionary dynamics of imatinib-treated leukemic cells by stochastic approach. Cent Eur J Phys 7:541\u2013548","journal-title":"Cent Eur J Phys"},{"key":"127_CR27","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1038\/leu.2009.32","volume":"23","author":"D Rea","year":"2009","unstructured":"Rea D, Etienne G, Corm S, Cony-Makhoul P, Gardembas M, Legros L, Dubruille V, Hayette S, Mahon F-X, Cayuela J-M, Nicolini FE (2009) Imatinib dose escalation for chronic phase-chronic myelogenous leukaemia patients in primary suboptimal response to imatinib 400\u00a0mg daily standard therapy. Leukemia 23:1193\u20131196","journal-title":"Leukemia"},{"key":"127_CR28","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1038\/nm1487","volume":"12","author":"I Roeder","year":"2006","unstructured":"Roeder I, Horn M, Glauche I, Hochhaus A, Mueller MC, Loeffler M (2006) Dynamic modeling of imatinib-treated chronic myeloid leukemia: functional insights and clinical implications. Nat Med 12:1181\u20131184","journal-title":"Nat Med"},{"key":"127_CR29","doi-asserted-by":"crossref","first-page":"4518","DOI":"10.1158\/0008-5472.CAN-07-5999","volume":"68","author":"GJ Sabnis","year":"2008","unstructured":"Sabnis GJ, Macedo LF, Goloubeva O, Schayowitz A, Brodie AMH (2008) Stopping treatment can reverse acquired resistance to letrozole. Cancer Res 68:4518\u20134524","journal-title":"Cancer Res"},{"key":"127_CR30","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1038\/ncponc1180","volume":"5","author":"B Seruga","year":"2008","unstructured":"Seruga B, Tannock IF (2008) Intermittent androgen blockade should be regarded as standard therapy in prostate cancer. Nat Clin Pract Oncol 5:574\u2013576","journal-title":"Nat Clin Pract Oncol"},{"key":"127_CR31","doi-asserted-by":"crossref","first-page":"3204","DOI":"10.1200\/JCO.2007.14.9260","volume":"26","author":"NP Shah","year":"2008","unstructured":"Shah NP, Kantarjian HM, Kim D, R\u00e9a D, Dorlhiac-Llacer PE, Milone JH, Vela-Ojeda J, Silver RT, Khoury HJ, Charbonnier A, Khoroshko N, Paquette RL, Deininger M, Collins RH, Otero I, Hughes T, Bleickardt E, Strauss L, Francis S, Hochhaus A (2008) Intermittent target Inhibition with dasatinib 100\u00a0mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia. J Clin Oncol 26:3204\u20133212","journal-title":"J Clin Oncol"},{"key":"127_CR32","first-page":"49","volume":"25","author":"JE Sokal","year":"1988","unstructured":"Sokal JE, Baccarani M, Russo D, Tura S. (1988) Staging and prognosis in chronic myelogenous leukemia. Semin Hematol 25:49\u201361","journal-title":"Semin Hematol"},{"key":"127_CR33","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1038\/84683","volume":"7","author":"P Vigneri","year":"2001","unstructured":"Vigneri P, Wang JY (2001) Induction of apoptosis in chronic myelogenous leukemia cells throught nuclear entrapment of BCR\u2013ABL tyrosine kinase. Nat Med 7:228\u2013234","journal-title":"Nat Med"},{"key":"127_CR34","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1054\/drup.2001.0180","volume":"4","author":"E Weisberg","year":"2001","unstructured":"Weisberg E, Griffin JD (2001) Mechanisms of resistance imatinib (STI571) in preclinical models and in leukemia patients. Drugs Resist Updat 4:22\u201328","journal-title":"Drugs Resist Updat"},{"key":"127_CR35","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/S1368-7646(03)00062-1","volume":"6","author":"E Weisberg","year":"2003","unstructured":"Weisberg E, Griffin JD (2003) Resistance to imatinib (Glivec): update on clinical mechanisms. Drugs Resist Updat 6:231\u2013238","journal-title":"Drugs Resist Updat"},{"key":"127_CR36","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1007\/s00249-008-0341-9","volume":"37","author":"VP Zhdanov","year":"2008","unstructured":"Zhdanov VP (2008) Stochastic model of the formation of cancer metastases via cancer stem cells. Eur Biophys J 37:1329\u20131334","journal-title":"Eur Biophys J"}],"container-title":["Theory in Biosciences"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12064-011-0127-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12064-011-0127-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12064-011-0127-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,21]],"date-time":"2021-11-21T09:43:16Z","timestamp":1637487796000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12064-011-0127-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,4,9]]},"references-count":36,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,9]]}},"alternative-id":["127"],"URL":"https:\/\/doi.org\/10.1007\/s12064-011-0127-y","relation":{},"ISSN":["1431-7613","1611-7530"],"issn-type":[{"value":"1431-7613","type":"print"},{"value":"1611-7530","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,4,9]]}}}